GIM
LENZ

Granahan Investment Management’s LENZ Therapeutics LENZ Stock Holding History

Granahan Investment Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-431,100
Closed -$6.9M – 173
2025
Q4 		$6.9M Buy
431,100
+239,703
+125% +$6.99M 0.3% 80
2025
Q3 		$8.92M Buy
191,397
+8,145
+4% +$300K 0.37% 66
2025
Q2 		$5.37M Buy
183,252
+7,086
+4% +$193K 0.22% 98
2025
Q1 		$4.53M Buy
176,166
+124,324
+240% +$3.06M 0.23% 98
2024
Q4 		$1.5M Buy
+51,842
New +$1.58M 0.06% 153

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Granahan Investment Management's LENZ Position: Q1 2026 in Review

Granahan Investment Management sold out of LENZ Therapeutics (LENZ) in Q1 2026, closing a stake of 431,100 shares — an estimated $6.9M sold.

Granahan Investment Management first reported a position in LENZ in Q4 2024 and held it in 5 quarters. The position peaked at $8.92M in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Granahan Investment Management reported no remaining LENZ Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Granahan Investment Management sold 431,100 LENZ Therapeutics shares in Q1 2026, an estimated $6.9M.
  • Granahan Investment Management first reported a position in LENZ Therapeutics in Q4 2024 and held it in 5 quarters.
  • Granahan Investment Management's LENZ Therapeutics position peaked at $8.92M in Q3 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Granahan Investment Management's 13F filing for Q1 2026, filed 15 May 2026.